- DE40 gains after Christmas break
- Deutsche Börse to start share buyback program on January 2, 2024
- Adler gains after Bafin audit completed
Overall market situation:
Market volatility in the last days of 2023 remain limited, nevertheless, we can see increased buying activity on the European trading floors themselves. The German DAX index is currently gaining more than 0.23%. The macro calendar scheduled for today's session is almost empty.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
European companies listed during Wednesday's trading session are mostly gaining at the moment. Source: xStation 5
The German benchmark DE40 is gaining nearly 0.08% during today's session. It is worth noting that the volume still indicates a lull in market volatility. The benchmark remains in the zone of its historical maxima. Source: xStation
News:
AstraZeneca (AZN.SE) has agreed to buy Nasdaq-listed Gracell Biotechnologies for about $1.2 billion for the clinical-stage biotech company. The deal is forecast to close in the first quarter of 2024. The company's shares are currently gaining nearly 1.3%.
German chemical giant Bayer AG (BAYN.DE) announced that it has won a lawsuit brought by a man who claimed that exposure to the herbicide Roundup caused him to develop cancer. It's worth remembering, however, that just a week ago a U.S. court ordered the company to pay nearly $857 million in damages to victims in the city of Seattle.
Deutsche Börse (DB1.DE) will begin a share buyback program on January 2, 2024. The buyback of up to 14 million shares is expected to end no later than May 3, 2024.
Adler (ADJ.DE) is currently gaining more than 13% following the outcome of a completed Bafin supervisory examination, which did not order a restatement or impose a fine, but identified accounting errors in the consolidated financial statements for 2020 and 2021 and ordered their publication.
